• Cybin outlined Phase 3 dosing underway for HLP003 in adjunctive major depressive disorder; FDA Breakthrough Therapy Designation highlighted.
• Phase 3 APPROACH topline data targeted for Q4 2026; HLP004 positioned in generalized anxiety disorder with Phase 2 signal-finding complete.
• Cash position of US$ 157.3 million as of March 31, 2026; completed a US$ 50 million underwritten offering in June 2026.
• IP portfolio cited at over 350 filed patents with over 100 granted; issued patents framed as providing protection until at least 2041.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cybin Inc. published the original content used to generate this news brief on June 29, 2026, and is solely responsible for the information contained therein.